Cresset is the distributor of COSMOlogic software to pharmaceutical companies in North America.
COSMOlogic applications provide robust predictions of fluid phase properties and is very widely used in synthetic chemistry, chemical engineering and drug development.
The Cambridge Crystallographic Data Centre (CCDC) is dedicated to the advancement of chemistry and crystallography for the public benefit through providing high quality information, software and services.
CCDC and Cresset work together to make the fragments and conformations from the Cambridge Structural Database (CSD), the world’s only comprehensive, up-to-date, and fully-curated knowledge base of small molecule crystal structures, accessible through Spark.
Cresset and Domainex have formed an alliance to provide their customers with world-class laboratory-based and computational drug discovery services through a seamless combination of their respective capabilities in chemistry and biology.
The alliance will give clients fully-integrated access to the renowned expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry; and to Cresset’s world-class approach to hit identification and drug design using its proprietary computational technologies.
Isogenica provides a biologics discovery service including library supply to the life science industry.
Cresset partners with Isogenica as part of a project to develop a highly-scalable approach to small molecule drug discovery.
Optibrium makes software that guides decisions involving complex, uncertain data in an intuitive way. Their primary product is StarDrop, which helps researchers deliver optimally balanced drugs.
Cresset and Optibrium work together to develop next generation products, with a two-way exchange of technology that brings better products to the drug discovery community.
Combining Cresset’s computational chemistry expertise with Peakdale’s experimental chemistry and biology capabilities, enabling delivery of fully integrated drug discovery programmes from leaders in their respective fields.
This collaboration brings together the collective knowledge of over 120 scientists with experience on over ninety biological targets across more than ten therapeutic areas.